Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Ocrevus
Ocrevus is a medicine used to treat multiple sclerosis, helping reduce relapses and slow progression of disability.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ocrelizumab
Ocrelizumab is a substance used to treat multiple sclerosis by targeting specific immune cells to reduce inflammation and nerve damage.
Rituximab
Rituximab is a substance that targets and reduces B cells, a type of white blood cell, to treat some blood cancers and autoimmune conditions.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
CHU Gabriel-Montpied
Neurologie
Beaumont, France
Hopital Purpan
Neurologie
Blagnac, France
Hospices Civils De Lyon
Neurologie
Bron, France

Sponsor: CHU De Rennes
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.